BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 36807512)

  • 1. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial.
    Giacoppo D; Alvarez-Covarrubias HA; Koch T; Cassese S; Xhepa E; Kessler T; Wiebe J; Joner M; Hochholzer W; Laugwitz KL; Schunkert H; Kastrati A; Kufner S
    Eur Heart J; 2023 Apr; 44(15):1343-1357. PubMed ID: 36807512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.
    Kufner S; Cassese S; Valeskini M; Neumann FJ; Schulz-Schüpke S; Hoppmann P; Fusaro M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2015 Jun; 8(7):877-84. PubMed ID: 26003022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis.
    Giacoppo D; Alfonso F; Xu B; Claessen BEPM; Adriaenssens T; Jensen C; Pérez-Vizcayno MJ; Kang DY; Degenhardt R; Pleva L; Baan J; Cuesta J; Park DW; Kukla P; Jiménez-Quevedo P; Unverdorben M; Gao R; Naber CK; Park SJ; Henriques JPS; Kastrati A; Byrne RA
    J Am Coll Cardiol; 2020 Jun; 75(21):2664-2678. PubMed ID: 32466881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
    Rittger H; Wöhrle J; Brachmann J; Hohenforst-Schmidt W; Schlundt C; Lonke S; von Cranach M; Markovic S; Achenbach S; Waliszewski M
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):529-534. PubMed ID: 26893095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis.
    Koch T; Lenz T; Rheude T; Cassese S; Kazazi M; Xhepa E; Kessler T; Wiebe J; Ferenc M; Laugwitz KL; Joner M; Schunkert H; Kastrati A; Kufner S
    JACC Cardiovasc Interv; 2024 Jan; 17(1):1-13. PubMed ID: 37902151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter).
    Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J
    JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: Insights from the French "real-world" prospective GARO Registry.
    Auffret V; Berland J; Barragan P; Waliszewski M; Bonello L; Delarche N; Furber A; Albert F; Carrié D; Eltchaninoff H; Pansieri M; Schneeberger M; Piot C; Marcollet P; Bedossa M
    Int J Cardiol; 2016 Jan; 203():690-6. PubMed ID: 26583844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.
    Xu B; Qian J; Ge J; Wang J; Chen F; Chen J; Wei M; Chen Y; Yang Y; Gao R;
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():624-9. PubMed ID: 26775079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon.
    Ali RM; Abdul Kader MASK; Wan Ahmad WA; Ong TK; Liew HB; Omar AF; Mahmood Zuhdi AS; Nuruddin AA; Schnorr B; Scheller B
    JACC Cardiovasc Interv; 2019 Mar; 12(6):558-566. PubMed ID: 30898253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
    Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcome of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation for the Treatment of Coronary Drug-Eluting Stent In-Stent Chronic Total Occlusion.
    Zhang Y; Wu Z; Wang S; Liu T; Liu J
    Cardiovasc Drugs Ther; 2023 Dec; 37(6):1155-1166. PubMed ID: 35930211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials.
    Koch T; Cassese S; Xhepa E; Mayer K; Tölg R; Hoppmann P; Laugwitz KL; Byrne RA; Kastrati A; Kufner S
    Catheter Cardiovasc Interv; 2020 Nov; 96(5):1008-1015. PubMed ID: 31789486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.
    Kufner S; Joner M; Schneider S; Tölg R; Zrenner B; Repp J; Starkmann A; Xhepa E; Ibrahim T; Cassese S; Fusaro M; Ott I; Hengstenberg C; Schunkert H; Abdel-Wahab M; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2017 Jul; 10(13):1332-1340. PubMed ID: 28683939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
    King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective trial of a novel low-dose paclitaxel-coated balloon therapy in patients with restenosis in drug-eluting coronary stents Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-stent REstenosis 3A (ISAR-DESIRE 3A).
    Kufner S; Rai H; Wiebe J; Altevogt F; Pyxaras S; Joner M; Xhepa E; Cassese S; Colleran R; Schunkert H; Zrenner B; Kastrati A; Byrne RA;
    Catheter Cardiovasc Interv; 2022 Feb; 99(3):754-762. PubMed ID: 34791755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial.
    Loh JP; Stella PR; Sangiorgi G; Silber S; Stahnke S; von Strandmann RP; Torguson R; Waksman R
    Cardiovasc Revasc Med; 2014 Jan; 15(1):23-8. PubMed ID: 24444473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of two paclitaxel-coated balloons with different excipient coatings in patients with coronary in-stent restenosis: A pooled analysis of the Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 3 and 4 (ISAR-DESIRE 3 and ISAR-DESIRE 4) trials.
    Colleran R; Joner M; Kufner S; Altevogt F; Neumann FJ; Abdel-Wahab M; Bohner J; Valina C; Richardt G; Zrenner B; Cassese S; Ibrahim T; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
    Int J Cardiol; 2018 Feb; 252():57-62. PubMed ID: 29203209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis.
    Almalla M; Schröder J; Pross V; Marx N; Hoffmann R
    Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.